Cassava Sciences, Inc. (SAVA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Austin, TX, 美国. 现任CEO为 Richard Jon Barry.
SAVA 拥有 IPO日期为 2000-07-14, 30 名全职员工, 在 NASDAQ Capital Marke, 市值为 $94.44M.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
